{
  "report_rows": [
    {
      "kpi": "Adjusted diluted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$4.45 vs. cons $4.37",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "U.S. Healthcare Solutions operating income",
      "prediction": "BEAT",
      "answer": "pred ~$1.07B vs. cons $1.04B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Consolidated revenue",
      "prediction": "IN-LINE",
      "answer": "pred ~$84.25B vs. cons $84.35B",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY26 adjusted diluted EPS guidance",
      "prediction": "BETTER",
      "answer": "guide ~$17.88 midpoint vs. cons $17.79 (FY26)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY26 consolidated revenue-growth guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~5.0% midpoint vs. cons 5.0% (FY26)",
      "confidence": "HIGH"
    },
    {
      "kpi": "FY26 U.S. Healthcare Solutions operating-income-growth guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~15.0% midpoint vs. cons 15.0% (FY26)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY26 adjusted free-cash-flow guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~$3.00B vs. cons $3.00B (FY26)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 2.8,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 1.0,
  "day5_path": "FADE",
  "day5_rationale": "A modest EPS and U.S. operating-income beat, plus a small FY26 EPS-guide increase, should initially validate earnings quality. However, an unchanged 4%-6% revenue framework and only modest guide upside leave implied fiscal-Q4 EPS at roughly $4.55 versus ~$4.60 in prior consensus math, limiting out-period estimate revisions after the initial move.",
  "day5_confidence": "MEDIUM"
}